National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 4) (PB 37 of 2018) (Cth)

Case

PB 37 of 2018

National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 4)

National Health Act 1953

___________________________________________________________________________

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated    29 May 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

_________________________________________________________________________

  1. Name of Instrument

(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2018 (No. 4).

(2)This Instrument may also be cited as PB 37 of 2018.

  1. Commencement

This Instrument commences on 1 June 2018.

  1. Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

  1. Schedule 1, omit entry for Aciclovir

  1. Schedule 1, before entry for Alendronic acid with colecalciferol

insert:

Acarbose Tablet 50 mg Oral Glucobay 50 90 18.14 20.64
Tablet 100 mg Oral Glucobay 100 90 25.69 28.19

  1. Schedule 1, entry for Carmellose in the form Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30

(a)omit from the column headed “Determined Price”:           6.37        substitute:             5.45

(b)omit from the column headed “Claimed Price”:                 8.63        substitute:             7.38

  1. Schedule 1, entry for Carmellose in the form Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30

(a)omit from the column headed “Determined Price”:           6.37        substitute:             5.45

(b)omit from the column headed “Claimed Price”:                 8.63        substitute:             7.38

  1. Schedule 1, entry for Doxepin in the form Capsule 10 mg (as hydrochloride)

(a)omit from the column headed “Determined Price”:           3.49        substitute:             2.98

(b)omit from the column headed “Claimed Price”:                 10.00     substitute:             8.55

  1. Schedule 1, entry for Doxepin in the form Capsule 25 mg (as hydrochloride)

(a)omit from the column headed “Determined Price”:           4.52        substitute:             3.86

(b)omit from the column headed “Claimed Price”:                 11.03     substitute:             9.43

  1. Schedule 1, after entry for Duloxetine in the form Capsule 60 mg (as hydrochloride)

insert:

Dutasteride Capsule 500 micrograms Oral Avodart 30 15.50 18.29

  1. Schedule 1, entry for Lisinopril in the form Tablet 5 mg

omit from the column headed “Claimed Price”:   5.08        substitute:             5.51

  1. Schedule 1, entry for Lisinopril in the form Tablet 10 mg

omit from the column headed “Claimed Price”:   6.08        substitute:             6.51

  1. Schedule 1, entry for Lisinopril in the form Tablet 20 mg

omit from the column headed “Claimed Price”:   6.86        substitute:             7.29

  1. Schedule 1, entry for Naratriptan in the form Tablet 2.5 mg (as hydrochloride)

(a)   omit from the column headed “Determined Price”:                                7.49        substitute:             6.40

(b)   omit from the column headed “Claimed Price”:                      8.55        substitute:             7.31

  1. Schedule 1, entry for Nifedipine in the form Tablet 20 mg

omit from the column headed “Claimed Price”:   7.84        substitute:             9.84

  1. Schedule 1, entry for Nifedipine in the form Tablet 30 mg (controlled release)

omit from the column headed “Claimed Price”:   8.75        substitute:             10.75

  1. Schedule 1, entry for Nifedipine in the form Tablet 60 mg (controlled release)

omit from the column headed “Claimed Price”:   10.53     substitute:             12.53

  1. Schedule 1, entry for Telmisartan in the form Tablet 40 mg

omit from the column headed “Claimed Price”:   3.78        substitute:             5.15

  1. Schedule 1, entry for Telmisartan in the form Tablet 80 mg

omit from the column headed “Claimed Price”:   6.91        substitute:             8.28

  1. Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-5 mg (as besylate)

omit from the column headed “Claimed Price”:   4.65        substitute:             5.92

  1. Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 40 mg-10 mg (as besylate)

omit from the column headed “Claimed Price”:   5.30        substitute:             6.52

  1. Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-5 mg (as besylate)

omit from the column headed “Claimed Price”:   7.72        substitute:             9.05

  1. Schedule 1, entry for Telmisartan with amlodipine in the form Tablet 80 mg-10 mg (as besylate)

omit from the column headed “Claimed Price”:   8.35        substitute:             9.65

  1. Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 40 mg-12.5 mg

omit from the column headed “Claimed Price”:   4.62        substitute:             5.62

  1. Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-12.5 mg

omit from the column headed “Claimed Price”:   7.79        substitute:             8.79

  1. Schedule 1, entry for Telmisartan with hydrochlorothiazide in the form Tablet 80 mg-25 mg

omit from the column headed “Claimed Price”:   8.26        substitute:             9.26

Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0